

# Collateral Therapeutics Incorporated

[View the current Collateral Therapeutics Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/2882-Collateral+Therapeutics+Incorporated.html)

(<http://www.bioportfolio.com/bi corporate/2882-Collateral+Therapeutics+Incorporated.html>)

## Contact Details:

11622 El Camino Real

San Diego

ca

92130

United States of America

Tel: 858.794.3400

Fax: 858.794.3440

Email: [info@collateralthx.com](mailto:info@collateralthx.com)

Collateral's initial non-surgical gene therapy products under investigation are designed to promote and enhance angiogenesis, a natural biological process which results in the growth of additional blood vessels, to increase levels of blood flow to oxygen-deprived tissues.

The Company's angiogenic products are administered using methods of gene therapy based on non-surgical adenoviral vector delivery of angiogenic genes. In addition to the Company's angiogenic product candidates, the Company is actively researching gene therapy products designed to increase responsiveness of the heart to adrenergic stimulation and to stimulate heart muscle regeneration.

The Company's lead product candidate, GENERX™ (Ad5-FGF4) is a non-surgical angiogenic gene therapy, which is being developed as a potential treatment for patients with stable exertional angina (chest pain) due to coronary artery disease (CAD).

## Recent Publications by Collateral Therapeutics Incorporated:



- [Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus.](#)  
*The presence of anti-adenoviral serotype 5 (Ad5) antibodies may limit the...* 11th March, 2006  
Collateral Therapeutics Inc., San Diego, CA 92130, USA.- Hum Gene Ther. 2006 Feb;17(2):230-8. ([DOI Direct Link](#))
- [Controlled expression of cardiac-directed adenyl cyclase type VI provides increased contractile function.](#)  
*OBJECTIVE: We have previously shown that cardiac-directed expression of...* 18th December, 2002  
Collateral Therapeutics Incorporated, San Diego, CA, USA.- Cardiovasc Res. 2002 Nov;56(2):197-204.

**Press Releases on Collateral Therapeutics Incorporated:**

<a href="#">Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger</a>	23rd November, 2009	Anesiva, Inc.	SOUTH SAN FRANCISCO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that Dr. Ted W. Love and Dr. David C. U&apos;Prichard have agreed to join the Anesiva board
<a href="#">Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal</a>	20th November, 2009	Cornerstone Therapeutics Inc.	CARY, N.C., Nov. 20 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products
<a href="#">H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics</a>	20th November, 2009	Quest Diagnostics Incorporated	-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during
<a href="#">Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth</a>	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to
<a href="#">New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)</a>	20th November, 2009	Quest Diagnostics Incorporated	MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation&apos;s leading provider of employment-related drug testing services,

**BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

